Advances in the Development of Antiviral Compounds for Rotavirus Infections

Group A rotaviruses (RVAs) are the major cause of severe acute gastroenteritis (AGE) in children under 5 years of age, annually resulting in nearly 130,000 deaths worldwide. Social conditions in developing countries that contribute to decreased oral rehydration and vaccine efficacy and the lack of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: María Julieta Tohmé, Laura Ruth Delgui
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://doaj.org/article/c4f9acf65eb1487e8b511935630f3f91
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c4f9acf65eb1487e8b511935630f3f91
record_format dspace
spelling oai:doaj.org-article:c4f9acf65eb1487e8b511935630f3f912021-11-03T21:15:05ZAdvances in the Development of Antiviral Compounds for Rotavirus Infections2150-751110.1128/mBio.00111-21https://doaj.org/article/c4f9acf65eb1487e8b511935630f3f912021-06-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00111-21https://doaj.org/toc/2150-7511 Group A rotaviruses (RVAs) are the major cause of severe acute gastroenteritis (AGE) in children under 5 years of age, annually resulting in nearly 130,000 deaths worldwide. Social conditions in developing countries that contribute to decreased oral rehydration and vaccine efficacy and the lack of approved antiviral drugs position RVA as a global health concern.María Julieta TohméLaura Ruth DelguiAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 12, Iss 3 (2021)
institution DOAJ
collection DOAJ
language EN
topic Microbiology
QR1-502
spellingShingle Microbiology
QR1-502
María Julieta Tohmé
Laura Ruth Delgui
Advances in the Development of Antiviral Compounds for Rotavirus Infections
description Group A rotaviruses (RVAs) are the major cause of severe acute gastroenteritis (AGE) in children under 5 years of age, annually resulting in nearly 130,000 deaths worldwide. Social conditions in developing countries that contribute to decreased oral rehydration and vaccine efficacy and the lack of approved antiviral drugs position RVA as a global health concern.
format article
author María Julieta Tohmé
Laura Ruth Delgui
author_facet María Julieta Tohmé
Laura Ruth Delgui
author_sort María Julieta Tohmé
title Advances in the Development of Antiviral Compounds for Rotavirus Infections
title_short Advances in the Development of Antiviral Compounds for Rotavirus Infections
title_full Advances in the Development of Antiviral Compounds for Rotavirus Infections
title_fullStr Advances in the Development of Antiviral Compounds for Rotavirus Infections
title_full_unstemmed Advances in the Development of Antiviral Compounds for Rotavirus Infections
title_sort advances in the development of antiviral compounds for rotavirus infections
publisher American Society for Microbiology
publishDate 2021
url https://doaj.org/article/c4f9acf65eb1487e8b511935630f3f91
work_keys_str_mv AT mariajulietatohme advancesinthedevelopmentofantiviralcompoundsforrotavirusinfections
AT lauraruthdelgui advancesinthedevelopmentofantiviralcompoundsforrotavirusinfections
_version_ 1718445420654362624